Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of “Buy” from Analysts

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been assigned a consensus recommendation of “Buy” from the fourteen analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $115.5455.

DNTH has been the subject of several analyst reports. William Blair reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Monday, March 16th. Stifel Nicolaus set a $120.00 price objective on shares of Dianthus Therapeutics in a research note on Monday, March 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st. Wedbush upped their target price on shares of Dianthus Therapeutics from $55.00 to $80.00 and gave the company an “outperform” rating in a research report on Tuesday, March 10th. Finally, Wells Fargo & Company assumed coverage on Dianthus Therapeutics in a research report on Thursday, March 19th. They issued an “overweight” rating and a $135.00 price target on the stock.

Insider Buying and Selling

In related news, CEO Marino Garcia sold 122,918 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $10,016,587.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Simrat Randhawa sold 33,830 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.48, for a total transaction of $2,756,468.40. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 323,021 shares of company stock valued at $26,564,008. Insiders own 8.15% of the company’s stock.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Patient Square Capital LP acquired a new stake in Dianthus Therapeutics during the 3rd quarter worth approximately $4,919,000. Vanguard Group Inc. boosted its holdings in shares of Dianthus Therapeutics by 13.6% in the third quarter. Vanguard Group Inc. now owns 1,642,198 shares of the company’s stock valued at $64,620,000 after buying an additional 196,117 shares during the period. Braidwell LP acquired a new position in shares of Dianthus Therapeutics in the third quarter valued at approximately $32,859,000. Fairmount Funds Management LLC increased its position in shares of Dianthus Therapeutics by 22.2% during the third quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock worth $130,138,000 after acquiring an additional 600,000 shares in the last quarter. Finally, Citigroup Inc. increased its position in shares of Dianthus Therapeutics by 486.8% during the third quarter. Citigroup Inc. now owns 68,479 shares of the company’s stock worth $2,695,000 after acquiring an additional 56,809 shares in the last quarter. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Stock Up 0.9%

DNTH stock opened at $95.76 on Thursday. Dianthus Therapeutics has a twelve month low of $16.64 and a twelve month high of $96.04. The company has a market cap of $5.21 billion, a P/E ratio of -23.36 and a beta of 1.22. The business has a fifty day moving average of $70.00 and a 200-day moving average of $50.98.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Monday, March 9th. The company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). The firm had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative return on equity of 38.85% and a negative net margin of 7,973.33%. As a group, equities research analysts anticipate that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.